WASHINGTON, DC — The U.S. Food and Drug Administration is warning consumers to check their medicine cabinets after a nationwide recall of thousands of blood pressure medication bottles. The recall involves certain lots of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets made by New Jersey-based Macleods Pharma USA.
According to the FDA, the action was first issued on Oct. 7, 2026, and later received a Class II designation on Oct. 26, 2026. That classification means use of the affected medicine may cause temporary or medically reversible health consequences, but the risk is not considered the most severe category.
Which bottles are included in the recall
The FDA says the recall covers 3,528 bottles containing 30 tablets each from lot 12251163A and 216 bottles containing 90 tablets each from lot 12251163B. Both lots have an expiration date of May 31, 2027.
Consumers who have these medications are being urged to compare the lot numbers on their bottles with the recall notice. The FDA’s warning applies to the specific lots identified in the agency’s enforcement report, not to every bottle of the medication sold in the United States.
Why regulators say the medication failed quality standards
The FDA said the tablets failed quality testing because they did not dissolve as required. That kind of problem can matter because the way a tablet breaks down affects how a patient’s body absorbs the medicine.
The agency did not say in the notice that it had linked the recalled bottles to injuries or illnesses. The recall was based on the quality failure identified during testing, which triggered the company action and the FDA’s subsequent classification.
What Class II means for patients and pharmacies
A Class II recall is used when exposure to a product may lead to temporary health effects or effects that are medically reversible. It is less serious than a Class I recall, which covers situations involving a reasonable probability of serious injury or death.
For patients, the practical takeaway is that the medication should be checked carefully and handled according to recall instructions. Pharmacies and distributors may also need to review inventory tied to the affected lot numbers so those bottles do not remain in circulation.
A second blood pressure recall follows earlier chlorthalidone actions
The blood pressure recall comes after earlier problems involving another medicine from Inventia Healthcare. In June, the company recalled certain lots of chlorthalidone tablets, and on Sept. 3, 2026, it initiated another recall involving an additional lot of that medication.
The FDA later classified the Sept. 3 recall as Class II on Sept. 17, 2026. Together, the actions show that regulators have been monitoring quality issues in more than one blood pressure-related product this year.
What consumers should do if they have the affected medicine
People who find one of the recalled bottles should not ignore the notice. They should check the lot number and expiration date on the container and follow the instructions provided with the recall.
Because the FDA says the issue is tied to product quality, consumers should also contact their pharmacist or healthcare provider if they have questions about replacing the medication or what to take next. The recall notice is intended to help patients identify the specific bottles that were pulled from the market.
Leave a Reply